jRCT2080223979已完成1 期
A multicenter, open-label, non-controlled, dose-escalation study in patients with relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma (ONO-7705-01)
ONO PHARMACEUTICAL CO.,LTD.1 个研究点目标入组 18 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, Open-label, Non-controlled, Dose-escalation Study
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients who are able to stay in hospital from a day before starting the study drug of the first course until the end of the relevant tests on Day 28
- •Patients with relapsed/refractory MM or NHL
- •Patients who have received two or more lines of therapies for MM or NHL
排除标准
- •Patients with plasma cell leukemia (defined as a peripheral blood plasma cell count > 2.0*10^9/L by the standard classification method)
- •Patients with primary amyloidosis
- •Patients with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes)
- •Patients with acute lymphocytic leukemia
- •Patients with lymphoblastic lymphoma
- •Patients with Burkitt's lymphoma or Richter's Syndrome
结局指标
主要结局
-
safety tolerability of ONO-7705 in relapsed/refractory MM and NHL patients
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
ONO-7475 Phase I Study (ONO-7475-02)jRCT2080224028ONO PHARMACEUTICAL CO.,LTD.84
进行中（未招募）
不适用
ONO-7475-03 : ONO-7475 Phase 1 StudyjRCT2051210045Ono Pharmaceutical Co.,LTD75
已完成
1 期
ONO-7913 Phase I study (ONO-7913)jRCT2080225170ONO PHARMACEUTICAL CO., LTD.12
暂停
不适用
ONO-7913-02 : ONO-7913 Phase 1 StudyjRCT2031210139Ono Pharmaceutical Co.,LTD12
已完成
1 期
ONO-7912 Phase I Study (ONO-7912-01)jRCT2080225264ONO PHARMACEUTICAL CO., LTD.12